PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
29572225-7	2018	Enzalutamide-induced AR degradation was rescued by either proteasome inhibition or by knockdown of the AR ubiquitin ligase speckle-type POZ protein (SPOP).	enzalutamide	0-12	speckle type BTB/POZ protein	Homo sapiens	123-147	
33158056-11	2020	SPOP upregulation is one of the mechanisms by which enzalutamide exerts its efficacy.	enzalutamide	52-64	speckle type BTB/POZ protein	Homo sapiens	0-4	
33158056-12	2020	Consequently, phospho-resistant SPOP fully abrogates tumorigenesis and EMT in vivo, and renders CRPC cells sensitive to enzalutamide.	enzalutamide	120-132	speckle type BTB/POZ protein	Homo sapiens	32-36	
33158056-13	2020	While genomic mutations of SPOP can be treated with gene therapy, identification of AURKA as an upstream regulator of SPOP provides a powerful opportunity for retaining WT-SPOP in a vast majority of CRPC patients using AURKA inhibitors +- enzalutamide, thereby treating the disease and inhibiting its progression.	enzalutamide	239-251	speckle type BTB/POZ protein	Homo sapiens	118-122	
33158056-13	2020	While genomic mutations of SPOP can be treated with gene therapy, identification of AURKA as an upstream regulator of SPOP provides a powerful opportunity for retaining WT-SPOP in a vast majority of CRPC patients using AURKA inhibitors +- enzalutamide, thereby treating the disease and inhibiting its progression.	enzalutamide	239-251	speckle type BTB/POZ protein	Homo sapiens	118-122	
29572225-7	2018	Enzalutamide-induced AR degradation was rescued by either proteasome inhibition or by knockdown of the AR ubiquitin ligase speckle-type POZ protein (SPOP).	enzalutamide	0-12	speckle type BTB/POZ protein	Homo sapiens	149-153